Biogen Inc.

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
196.52 ^USD	+0.52%		-2.32%	+11.67%

02-13	Biogen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-13-2026 10:30 AM
02-12	Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…

UBS Adjusts Price Target on Biogen to $185 From $130, Maintains Neutral Rating

Published on 01/07/2026 at 03:44 pm GMT

MT Newswires

Latest news about Biogen Inc.

02-13	Biogen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-13-2026 10:30 AM
02-12	Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…
02-11	Biogen Inc. Announces Board Changes	CI
02-10	Biogen Insider Sold Shares Worth $531,548, According to a Recent SEC Filing	MT
02-09	Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says	MT
02-09	HC Wainwright Adjusts Price Target on Biogen to $228 From $194, Maintains Buy Rating	MT
02-09	RBC Raises Price Target on Biogen to $233 From $217, Keeps Outperform Rating	MT
02-09	Bernstein Adjusts Price Target on Biogen to $201 From $191, Maintains Market Perform Rating	MT
02-09	Piper Sandler Adjusts Price Target on Biogen to $177 From $157, Maintains Neutral Rating	MT
02-09	Citigroup Adjusts Price Target on Biogen to $215 From $185, Maintains Neutral Rating	MT
02-09	Guggenheim Adjusts Price Target on Biogen to $246 From $185, Maintains Buy Rating	MT
02-09	TD Cowen Adjusts Price Target on Biogen to $215 From $175, Maintains Buy Rating	MT
02-09	Analyst recommendations: Align, Take-Two, Biogen, PayPal, Stellantis…
02-09	Biogen says biologics license application for subcutaneous formulation of Leqembi for treatment of early Alzheimer's disease designated for Priority Review in China	RE
02-06	Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating	MT

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.

Employees

7,500

Sector

Pharmaceuticals

Calendar

05-05 - Q1 2026 Earnings Release (Projected)

More about the company